All In MedTech

Device Trial Radar · NCT06555848

CERAMENT G as Part of the Surgical Treatment of Osteomyelitis in a Single-Stage Procedure

A Post-Market Prospective Cohort Study on Subjects Receiving CERAMENT G as Part of the Surgical Treatment of Osteomyelitis in a Single-Stage Procedure

Last checked: Nov 19, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

128

Planned (sponsor's estimate)

Start

Jun 2, 2025

Primary completion

Oct 2031

Study completion Oct 2032

Sponsor

Lead sponsor
BONESUPPORT ABNot on our public-company list
Sponsor type
Industry
First posted
Aug 15, 2024

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a prospective cohort study of subjects where CERAMENT G was used as part of the surgical treatment of osteomyelitis in a single stage procedure.

Conditions

  • Osteomyelitis

Interventions

  • CERAMENT GDevice

    CERAMENT G is intended for use as a bone void filler as an adjunct to systemic antibiotic therapy and surgical debridement (standard treatment approach to a bone infection) as part of the surgical treatment of osteomyelitis. By eluting gentamicin, CERAMENT G can reduce the recurrence of chronic osteomyelitis from gentamicin-sensitive microorganisms in order to protect bone healing.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite EndpointTime frame: 36 months
  2. Co-Primary EndpointTime frame: 36 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bone Infection Unit, Nuffield Orthopaedic Centtre, Oxford University Hospitals, MHS

    Oxford, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.